Tough on the portfolio balance but my belief that SNTA is a great risk/reward play has not is still in tact, especially after listening to the latest ASCO presentation.
There was no hype or boasting. The company said that the next trial results will be what tells the story of Ganetespib, be it good or bad. Sure they see things they like in the latest data but they understand that more positive results are needed before the street and the FDA will go along for the ride.
The doctor who spoke of the patient that was doing very well on monotherapy seemed quite impressed with the drug. Yes one patient does not make a trial but his comments do lend support to us longs. Shorts will call it BS but I find it hard to believe that an oncologist is hyping something as he treats dying patients.
I realize that stocks like SNTA are a long shot but with Kovner taking a stab and the ASCO presentation, II see it as a worth while bet.